Skip to main content

Table 1 Clinicopathological features of 114 patients and chemo-effects

From: Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer

 

pCR

 

non-pCR

 

p value

n

11

 

103

  

Mean age (SD)

54.6

(16.4)

50.9

(11.1)

n.s.

Mean tumour sizea (mm) (SD)

35.9

(18.1)

36.0

(15.7)

n.s.

Histology

     

Ductal

11

 

98

 

n.s.

Lobular

0

 

5

  

High nuclear grade

27%

(3/11)

22%

(22/99)

n.s.

ERb

100%

(114/114)

100%

(114/114)

n.s.

PRb

45%

(5/11)

78%

(80/103)

<0.05

Mean Ki67 (%) (SD)c

43.0

(30.0)

33.6

(18.1)

<0.01

  1. ER: estrogen receptor, PR: progesterone receptor, n.s.: not significant.
  2. aclinical size measured by ultrasound before treatments.
  3. brates of positive (more than 10% of the nuclei of cancer cells) cases.
  4. cdot chart shown in Additional file 1: Figure S1.
  5. The NAC response was significantly better in patients with tumours highly expressing Ki67 (p < 0.01). PR-negative tumours also showed better responses to chemotherapy (p < 0.05).
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us